Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Expects Big Gains In APAC With Late-stage Pipeline And Zydus Cadila Joint Venture

This article was originally published in PharmAsia News

Executive Summary

Bayer expects half of its 43 clinical trials to be ready for the market in the next few years in Southeast Asia.

You may also be interested in...



In Transition? Bayer Exercises Option To Up Stake In JV With Zydus

Bayer is increasing its holding in its long-standing joint venture with Zydus Cadila in India by 25%, sparking off some speculation on the alliance’s future trajectory.

Bayer And Cadila Pool Products To Form Equal Stake JV For India Market

MUMBAI - A deal that has been brewing for nearly two years has finally taken a concrete shape. Germany's Bayer Healthcare and India's Zydus Cadila have agreed to form an equal stake company that will see Bayer move its existing sales and marketing business in India to the new enterprise

List Ahead For Southeast Asia Pharma In 2015

PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.

Topics

Related Companies

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel